Product launches – Crassula Pharmaceuticals https://crassulapharma.com Crassula Pharmaceuticals - Innovative Health Care Solutions Mon, 19 Oct 2026 23:10:23 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.4 https://crassulapharma.com/wp-content/uploads/2022/04/cropped-CRASSULA-LIFE-SCIENCE-01-32x32.png Product launches – Crassula Pharmaceuticals https://crassulapharma.com 32 32 Crassula Launches Vascutan Plus, Irbesartan/Hydrochlorothiazide, in Honduras https://crassulapharma.com/crassula-launches-vascutan-plus-irbesartan-hydrochlorothiazide-in-honduras/ https://crassulapharma.com/crassula-launches-vascutan-plus-irbesartan-hydrochlorothiazide-in-honduras/#respond Wed, 08 May 2024 13:58:31 +0000 https://crassulapharma.com/?p=7325 A combination of an angiotensin II receptor blocker and a thiazide diuretic that broadens Crassula’s hypertension portfolio in Honduras.

The post Crassula Launches Vascutan Plus, Irbesartan/Hydrochlorothiazide, in Honduras appeared first on Crassula Pharmaceuticals.

]]>

Crassula Launches Vascutan Plus, Irbesartan/Hydrochlorothiazide, in Honduras

Vascutan Plus v2

Tegucigalpa, Honduras – Continuing its commitment to cardiovascular health, Crassula Pharmaceuticals is proud to announce the release of Vascutan Plus, a combination medication containing Irbesartan and Hydrochlorothiazide, in Honduras. This new addition enhances Crassula’s portfolio by offering a comprehensive treatment solution for hypertension.

Vascutan Plus combines Irbesartan, an angiotensin II receptor blocker (ARB), with Hydrochlorothiazide, a thiazide diuretic. This synergistic combination not only effectively lowers blood pressure by relaxing blood vessels but also helps eliminate excess salt and water from the body, further reducing blood pressure and the strain on the cardiovascular system.

“Crassula Pharmaceuticals remains at the forefront of innovation in healthcare with the launch of Vascutan Plus, aimed at providing a more effective hypertension management strategy,” stated Dr. Roopesh Gupta, CEO of Crassula Pharmaceuticals. “This advanced formula is designed to meet the diverse needs of patients dealing with high blood pressure, offering them a higher level of care and support.”

Vascutan Plus is now available throughout Honduras, signifying a key advancement in the management of hypertension and its associated risks. For more information on Vascutan Plus and other products from Crassula Pharmaceuticals, please visit www.crassulapharma.com or contact sales@crassulapharma.com.

About Crassula Pharmaceuticals

Specializing in high-quality healthcare products, Crassula Pharmaceuticals focuses on innovation, quality, and patient safety to enhance health and well-being both locally and globally. The company offers a wide range of therapeutic solutions designed to address the healthcare needs of the community.

The post Crassula Launches Vascutan Plus, Irbesartan/Hydrochlorothiazide, in Honduras appeared first on Crassula Pharmaceuticals.

]]> https://crassulapharma.com/crassula-launches-vascutan-plus-irbesartan-hydrochlorothiazide-in-honduras/feed/ 0 Crassula Pharmaceuticals Launches Vascutan, Irbesartan, in Honduras https://crassulapharma.com/crassula-pharmaceuticals-launches-vascutan-irbesartan-in-honduras/ https://crassulapharma.com/crassula-pharmaceuticals-launches-vascutan-irbesartan-in-honduras/#respond Mon, 29 Apr 2024 19:55:10 +0000 https://crassulapharma.com/?p=7192 The market introduction of Vascutan expands Crassula’s cardiovascular portfolio for hypertension and associated cardiac conditions.

The post Crassula Pharmaceuticals Launches Vascutan, Irbesartan, in Honduras appeared first on Crassula Pharmaceuticals.

]]>

Crassula Introduces Vascutan for Advanced Hypertension Control in Honduras

Vascutan 300 v2

Tegucigalpa, Honduras – Crassula Pharmaceuticals, a leader in cardiovascular healthcare solutions, is thrilled to announce the market introduction of Vascutan, an Irbesartan-based medication, in Honduras. This strategic expansion of Crassula’s cardiovascular portfolio underscores the company’s commitment to combating hypertension and associated cardiac conditions.

Irbesartan, the active ingredient in Vascutan, is a potent angiotensin II receptor blocker (ARB) that effectively lowers blood pressure by relaxing blood vessels. The introduction of Vascutan aims to provide patients with a reliable and efficient option for managing hypertension, which is a major risk factor for heart disease and stroke.

“Crassula Pharmaceuticals is dedicated to enhancing patient health through innovative and effective treatments. The launch of Vascutan demonstrates our commitment to addressing the urgent needs of hypertensive patients,” said Mr. Arturo Yidi, COO of Crassula. “We believe Vascutan will play a critical role in improving the cardiovascular health of the Honduran population.”

Vascutan is now available in Honduras, providing a new tool in the fight against high blood pressure and its complications. For more information about Vascutan and other Crassula products, please visit www.crassulapharma.com or contact sales@crassulapharma.com.

About Crassula Pharmaceuticals

Crassula specializes in high-quality healthcare products that focus on innovation, quality, and patient safety. Our mission is to improve health and well-being in Honduras and beyond, with a diverse product range that addresses various therapeutic areas and healthcare needs.

Discover the Benefits of Vascutan for Hypertension Treatment

Lowered Blook Pressure

Lowered Blood Pressure

Vascutan is a Potent Angiotensin II Receptor Blocker (ARB) that Effectively Lowers Blood Pressure

Reduced Risk of Heart Disease

Reduced Risk of Heart Disease and Stroke

Vascutan Improves Overall Cardiovascular Health

Take Control

Take Control of Your Hypertension

Manage Your Serious Health Condition with Vascutan

Peace of Mind

Peace of Mind

Contact Us to Get Vascutan Today

Choose the Best Treatment for Hypertension

Vascutan is the right choice for those seeking effective treatment for high blood pressure. With Irbesartan as its key ingredient, Vascutan is a potent Angiotensin II receptor blocker (ARB) that relaxes blood vessels and effectively manages hypertension, reducing the risk of heart disease and stroke significantly. Take control of your health today and choose Vascutan. For more information, contact us at +1 954-676-7060 or email at info@crassulapharma.com.

By clicking Learn More, you’re confirming that you agree with our Terms and Conditions.

The post Crassula Pharmaceuticals Launches Vascutan, Irbesartan, in Honduras appeared first on Crassula Pharmaceuticals.

]]> https://crassulapharma.com/crassula-pharmaceuticals-launches-vascutan-irbesartan-in-honduras/feed/ 0 Introducing Glycedil: Revolutionizing Type 2 Diabetes Management in Honduras https://crassulapharma.com/introducing-glycedil-revolutionizing-type-2-diabetes-management-in-honduras/ https://crassulapharma.com/introducing-glycedil-revolutionizing-type-2-diabetes-management-in-honduras/#respond Tue, 26 Mar 2024 20:33:37 +0000 https://crassulapharma.com/?p=7142 Crassula Honduras expands its diabetes care portfolio with the launch of Glycedil, a sitagliptin 100 mg tablet.

The post Introducing Glycedil: Revolutionizing Type 2 Diabetes Management in Honduras appeared first on Crassula Pharmaceuticals.

]]>

Introducing Glycedil: Revolutionizing Type 2 Diabetes Management in Honduras

Glycedil
Crassula Honduras Announces the Launch of Glycedil, Sitagliptin 100mg, in Honduras

Tegucigalpa, Honduras – In a significant expansion of its diabetes care portfolio, Crassula Pharmaceuticals proudly introduces Glycedil, a Sitagliptin 100mg tablet, to the Honduran market. This strategic launch underscores Crassula’s unwavering commitment to innovating in the field of chronic disease management and improving the quality of life for individuals living with Type 2 diabetes.

Sitagliptin, the active ingredient in Glycedil, is a highly effective dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by enhancing the body’s own ability to lower blood sugar levels, especially after meals. The 100mg dosing of Glycedil is designed to optimize blood sugar control while minimizing side effects, offering a new hope for patients seeking a more balanced approach to managing their diabetes.

“Crassula Pharmaceuticals is dedicated to advancing healthcare outcomes with accessible, innovative treatments. The launch of Glycedil is a testament to our commitment to providing effective solutions for the complex challenges faced by patients with Type 2 diabetes,” said Dr. Josué Daniel Suazo, National Sales Manager at Crassula Honduras. “We are excited to offer this new therapeutic option to the people of Honduras, further enhancing our mission to make advanced care available to all.”

Glycedil is now available across Honduras, marking a pivotal step forward in the management of Type 2 diabetes. For more information on Glycedil and other Crassula products, please visit www.crassulapharma.com  or contact sales@crassulapharma.com

About Crassula Honduras

Crassula Honduras is a division of Crassula LLC., a USA based company at the forefront of developing high-quality healthcare products, focusing on innovation, quality, and patient safety to improve health and well-being both in Honduras and internationally. With a diverse product range that addresses a wide spectrum of therapeutic areas, Crassula is committed to meeting the healthcare needs of communities around the globe.

The post Introducing Glycedil: Revolutionizing Type 2 Diabetes Management in Honduras appeared first on Crassula Pharmaceuticals.

]]> https://crassulapharma.com/introducing-glycedil-revolutionizing-type-2-diabetes-management-in-honduras/feed/ 0 Crassula Launches Relixib, Etoricoxib 120mg Coated Tablet, in Honduras https://crassulapharma.com/crassula-launches-relixib-etoricoxib-120mg-coated-tablet-in-honduras/ https://crassulapharma.com/crassula-launches-relixib-etoricoxib-120mg-coated-tablet-in-honduras/#respond Sun, 24 Mar 2024 17:25:54 +0000 https://crassulapharma.com/?p=7084 Relixib joins the portfolio to address the needs of patients with chronic pain and inflammation.

The post Crassula Launches Relixib, Etoricoxib 120mg Coated Tablet, in Honduras appeared first on Crassula Pharmaceuticals.

]]>

Crassula Launches Relixib, Etoricoxib 120mg Coated Tablet, in Honduras

Relixib 120mg Comp
Crassula Pharmaceuticals Launches Relixib, Etoricoxib 120mg, in Honduras

Tegucigalpa, Honduras – Crassula Honduras, a leading pharmaceutical manufacturer renowned for its commitment to quality, is excited to announce the introduction of Relixib, an etoricoxib 120mg tablet, to the Honduran market. This new addition to Crassula’s portfolio reinforces the company’s dedication to providing advanced healthcare solutions and addressing the needs of patients suffering from chronic pain and inflammation.

Etoricoxib, the active ingredient in Relixib, belongs to a class of medications known as selective COX-2 inhibitors, offering targeted relief from pain and swelling associated with various arthritic conditions, including osteoarthritis, rheumatoid arthritis, and gout. The 120mg dosage has been carefully selected to optimize efficacy while minimizing potential side effects, ensuring a better quality of life for patients.

“Through the launch of Relixib, Crassula Honduras underscores its ongoing commitment to enhance healthcare outcomes with innovative and accessible treatment options. Relixib exemplifies our mission to address unmet medical needs in the management of pain and inflammation,” stated Dr. Bhawana Gupta, CTO of Crassula Pharmaceuticals. “We are proud to offer this significant advancement in pain management to the people of Honduras, furthering our goal of making superior healthcare solutions readily accessible.”

Relixib is now available in Honduras, offering a new hope for patients seeking effective management of chronic pain and inflammatory conditions. For more information about Relixib and other Crassula Pharmaceuticals products, please visit www.crassulapharma.com or contact sales@crassulapharma.com.

About Crassula Honduras

Crassula Honduras is a division of Crassula Pharmaceuticals, a company synonymous with high-quality healthcare products. With a focus on innovation, quality, and patient safety, Crassula strives to improve health and well-being in Honduras and beyond. The company’s diverse product portfolio meets a wide range of healthcare needs, ensuring that patients have access to the latest advancements in medical treatment.

The post Crassula Launches Relixib, Etoricoxib 120mg Coated Tablet, in Honduras appeared first on Crassula Pharmaceuticals.

]]> https://crassulapharma.com/crassula-launches-relixib-etoricoxib-120mg-coated-tablet-in-honduras/feed/ 0 Crassula Pharma Lauches In Honduras https://crassulapharma.com/press-release/ https://crassulapharma.com/press-release/#comments Thu, 01 Feb 2024 15:54:04 +0000 https://crassulapharma.com/?p=6388 Gasflum expands Crassula Honduras’ portfolio for the management of acid reflux and related conditions.

The post Crassula Pharma Lauches In Honduras appeared first on Crassula Pharmaceuticals.

]]>

Crassula Pharmaceuticals Launches in Honduras

Gasflum 40mg
Crassula Pharmaceuticals Launches Gasflum, Esomeprazole 40mg Coated Tablet, in Honduras

Tegucigalpa, Honduras – Crassula Honduras, a premier pharmaceutical manufacturer, proudly announces the launch of Gasflum, an esomeprazole 40mg coated tablet, enhancing its portfolio of high-quality healthcare solutions in Honduras. Designed for effective management of acid reflux and related conditions, Gasflum offers a significant advancement in treating gastroesophageal reflux disease (GERD), peptic ulcers, and excessive stomach acid production.

 

Esomeprazole, the active component of Gasflum, is a proton pump inhibitor (PPI) that effectively reduces stomach acid. The coated tablet formulation ensures ease of use and adherence, with a convenient once-daily dosing.

 

“Crassula Honduras is committed to improving healthcare outcomes with accessible and innovative treatments. Gasflum represents our dedication to providing effective solutions for managing gastrointestinal conditions,” said Dr. Roopesh Gupta, CEO at Crassula Pharmaceuticals. “We aim to enhance the quality of life for patients in Honduras, making advanced care readily available.”

 

For more details on Gasflum and other products, visit www.crassulapharma.com or contact sales@crassulapharma.com 

 

About Crassula Honduras

 

Crassula Honduras specializes in high-quality healthcare products, focusing on innovation, quality, and patient safety to improve health and well-being in Honduras and beyond. Our diverse product range addresses various therapeutic areas, meeting the healthcare needs of our community.

Estarol 20mg
Crassula Pharmaceuticals Launches Estarol, Atorvastatin 20mg and 40mg Coated Tablets, in Honduras

Tegucigalpa, Honduras – Crassula Honduras, a leader in pharmaceutical manufacturing, announces the launch of Estarol, atorvastatin in 20mg and 40mg coated tablets, reinforcing its commitment to advancing cardiovascular health in Honduras. Estarol is formulated to lower high cholesterol and reduce the risk of heart disease, showcasing Crassula Honduras’s dedication to offering comprehensive healthcare solutions.

 

Atorvastatin, the active ingredient in Estarol, is a statin medication that works by reducing the levels of bad cholesterol (LDL) and triglycerides in the blood while increasing good cholesterol (HDL). The availability of Estarol in both 20mg and 40mg dosages allows healthcare providers to tailor treatment to individual patient needs, enhancing the effectiveness of cholesterol management strategies.

 

“Estarol is a testament to Crassula Honduras’s ongoing commitment to provide innovative, accessible healthcare solutions,” said Ricardo Fiallos, Sales Director at Crassula Honduras. “With the launch of Estarol, we aim to address the growing need for effective cholesterol management options, contributing to the prevention of cardiovascular diseases and improving patient outcomes in Honduras.”

 

Estarol’s coated tablet formulation ensures ease of administration and patient compliance, with dosing flexibility to meet the therapeutic needs of a wide patient population.

 

For more information about Estarol and other Crassula Honduras products, please visit visit www.crassulapharma.com or contact sales@crassulapharma.com 

 

About Crassula Honduras

 

Crassula Honduras is committed to delivering high-quality healthcare products, emphasizing innovation, quality, and patient safety to enhance the health and well-being of individuals in Honduras and beyond. Our broad product portfolio addresses various therapeutic needs, fulfilling the healthcare requirements of our community.

 

The post Crassula Pharma Lauches In Honduras appeared first on Crassula Pharmaceuticals.

]]> https://crassulapharma.com/press-release/feed/ 2